Local pharmacies say they're struggling to afford GLP-1s
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.)
Harry Webb has seen a flurry of interest in popular weight loss drugs at his independent pharmacies in Indiana, but he doesn’t know how much longer he can afford to stock them.
Many local pharmacies are losing money on glucagon-like peptide-1 (GLP-1) receptor agonists like Novo Nordisk’s Ozempic and Wegovy as reimbursement rates come in below acquisition cost, according to an informal survey from the National Community Pharmacists Association. Respondents reported losing an average of more than $37 per 30-day supply, according to the unpublished survey.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.